- Home
- RNAZ vs POLA Comparison
RNAZ vs POLA Comparison
Compare RNAZ & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- POLA
- Stock Information
- Founded
- RNAZ 2016
- POLA 1979
- Country
- RNAZ United States
- POLA United States
- Employees
- RNAZ N/A
- POLA N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- POLA Industrial Machinery/Components
- Sector
- RNAZ Health Care
- POLA Miscellaneous
- Exchange
- RNAZ Nasdaq
- POLA Nasdaq
- Market Cap
- RNAZ 8.3M
- POLA 7.7M
- IPO Year
- RNAZ 2021
- POLA 2016
- Fundamental
- Price
- RNAZ $0.32
- POLA $0.46
- Analyst Decision
- RNAZ Strong Buy
- POLA
- Analyst Count
- RNAZ 1
- POLA 0
- Target Price
- RNAZ $3.00
- POLA N/A
- AVG Volume (30 Days)
- RNAZ 606.0K
- POLA 129.5K
- Earning Date
- RNAZ 11-26-2024
- POLA 11-19-2024
- Dividend Yield
- RNAZ N/A
- POLA N/A
- EPS Growth
- RNAZ N/A
- POLA N/A
- EPS
- RNAZ N/A
- POLA N/A
- Revenue
- RNAZ N/A
- POLA $11,950,000.00
- Revenue This Year
- RNAZ N/A
- POLA $6.72
- Revenue Next Year
- RNAZ $100.00
- POLA N/A
- P/E Ratio
- RNAZ N/A
- POLA N/A
- Revenue Growth
- RNAZ N/A
- POLA N/A
- 52 Week Low
- RNAZ $0.22
- POLA $0.32
- 52 Week High
- RNAZ $18.68
- POLA $0.95
- Technical
- Relative Strength Index (RSI)
- RNAZ 33.05
- POLA 52.73
- Support Level
- RNAZ $0.31
- POLA $0.43
- Resistance Level
- RNAZ $0.49
- POLA $0.53
- Average True Range (ATR)
- RNAZ 0.05
- POLA 0.05
- MACD
- RNAZ -0.02
- POLA 0.01
- Stochastic Oscillator
- RNAZ 12.67
- POLA 64.21
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About POLA Polar Power Inc.
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications primarily in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, Back-up DC generators, hybrid power systems, Li-Ion battery systems, and Marine DC generators. The Companie's geographical presence is in the United States, Canada, Mexico, South Pacific Islands, Japan, Europe and Middle East and Other Asia Pacific countries.